In focus · trending topic

PLK1 inhibitor

2 stories · following the connections

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

By Nasdaq OMXApr 4, 2017, 5:00 PM UTC

Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

By Nasdaq OMXApr 2, 2017, 5:00 PM UTC